Novo Nordisk sues Eli Lilly over alleged false advertising in weight loss drug marketing

Novo Nordisk has filed a lawsuit in U.S. federal court alleging Eli Lilly engaged in deceptive marketing by comparing its Zepbound and Mounjaro drugs against lower doses of Novo's products. The litigation centers on claims of unfair competition and violations of the Lanham Act, marking an escalation in the competitive landscape for GLP-1 receptor agonists.